SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-18-020274
Filing Date
2018-11-09
Accepted
2018-11-09 14:46:24
Documents
74
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20180930_10q.htm 10-Q 1080992
2 EXHIBIT 10.1 ex_128269.htm EX-10.1 22439
3 EXHIBIT 10.2 ex_128270.htm EX-10.2 122004
4 EXHIBIT 31.1 ex_128271.htm EX-31.1 9417
5 EXHIBIT 32.1 ex_128272.htm EX-32.1 4803
  Complete submission text file 0001437749-18-020274.txt   7399711

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20180930.xml EX-101.INS 1670809
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20180930.xsd EX-101.SCH 63876
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20180930_cal.xml EX-101.CAL 46602
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20180930_def.xml EX-101.DEF 576225
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20180930_lab.xml EX-101.LAB 410280
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20180930_pre.xml EX-101.PRE 588515
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 181172678
SIC: 2835 In Vitro & In Vivo Diagnostic Substances